Kezar Shifts Focus From Tumor Drug to Autoimmune Therapy
Kezar halts tumor drug trials, pivots to autoimmune hepatitis focus with promising zetomipzomib.
- Latest
- Trending
Kezar halts tumor drug trials, pivots to autoimmune hepatitis focus with promising zetomipzomib.
Bitcoin hits $61K on rate cut hopes; inflation data awaited. Institutional inflow remains limited, regulatory concerns persist.
Bitcoin's price drops below $59,000, leading to $132M in liquidations amid ongoing market turbulence.
Bitcoin's price dropped below $59,000, causing $132M liquidations. Market volatility highlights caution for investors.
Bitcoin dips 4% amid $156.4M liquidations, impacting broader crypto. Market remains volatile as traders face challenges.
LL Flooring seeks court approval for sale amid bankruptcy, securing $130M financing while negotiating with bidders.
Ethereum's price faces key resistance at $2.8K after a 37% crash. Is a bearish trend continuation likely, or will ETH ...
AI's role in digital economy poses challenges, particularly for women. Learn how AI affects women's opportunities and roles.
SEC postpones decision on Hashdex's crypto ETF to September, affecting Bitcoin and Ethereum markets.
Ethereum shows strength amid market optimism; traders eye $3000 target despite recent bearish pressure. Will the rally continue?
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.